SCHEMBL29035403

SCHEMBL29035403

CC(C)(C)OC(=O)N1CC(O)C[C@@H]1CO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
RIPK1 Q13546 1/20 0.39
SRC P12931 8/20 0.39
ABCB1 P08183 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NR1H2 P55055 2/20 0.36
NR1H3 Q13133 2/20 0.36
PARP1 P09874 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
SMYD2 Q9NRG4 1/20 0.35
GPR119 Q8TDV5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15345576 1.00 CYP1A2 (0.41) CYP1A2POLBCYP3A4CYP2C19RIPK1
SCHEMBL5152621 1.00 CYP1A2 (0.41) CYP1A2POLBCYP3A4CYP2C19RIPK1
SCHEMBL5152627 1.00 CYP1A2 (0.41) CYP1A2POLBCYP3A4CYP2C19RIPK1
SCHEMBL28396275 1.00 CYP1A2 (0.41) CYP1A2POLBCYP3A4CYP2C19RIPK1
SCHEMBL5150301 1.00 CYP1A2 (0.41) CYP1A2POLBCYP3A4CYP2C19RIPK1
SCHEMBL30743026 0.90 CYP1A2 (0.37) CYP1A2POLBCYP3A4CYP2C19SRC
SCHEMBL5151940 0.90 SRC (0.40) CYP1A2POLBCYP3A4CYP2C19SRC
SCHEMBL31122923 0.90 CYP1A2 (0.37) CYP1A2POLBCYP3A4CYP2C19SRC
SCHEMBL5152054 0.90 SRC (0.40) CYP1A2POLBCYP3A4CYP2C19SRC
SCHEMBL6543144 0.90 SRC (0.40) CYP1A2POLBCYP3A4CYP2C19SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117813298-A Imidazole indazole compounds as JAK inhibitors 施万生物制药研发IP有限责任公司 2024-04-02 CN disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed